Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trialGavin Brittain, John A. Snowden, Elisa Roldán et al.|BMJ Open|2024Cited by 10
Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with recessive dystrophic epidermolysis bullosa (MissionEB): a randomised, double-blind, placebo controlled, crossover, phase 3 trial with an internal phase 1 dose de-escalation phaseMaria L Bageta, Anna E. Martinez, Pablo López Balboa et al.|EClinicalMedicine|2025Cited by 1
O04 Mission EB -mesenchymal intravenous stromal cell infusions in children with recessive dystrophic epidermolysis bullosa: a randomised, double-blinded, placebo controlled, crossover trialMaria L Bageta, Anna E. Martinez, Pablo López Balboa et al.|British Journal of Dermatology|2025Cited by 0